Möchten Sie immer auf dem neuesten Stand bleiben?

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability

Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer

“Global Oncology Biosimilars Market” is projected to grow from $9.6 billion in 2025 to $17.5 billion by the end of 2030, at a CAGR of 12.6%.

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal...

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

Io Therapeutics reports publication of studies on its RXR agonist compound for prevention of Triple Negative Breast Cancer.

Commit Biologics appoints seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer.

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients